Evaluation of Ruxolitinib And Thalidomide Combination as a Therapy for Patients With Myelofibrosis
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary) ; Thalidomide (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Therapeutic Use
- 06 Nov 2019 Results (n=23) assessing safety and efficacy of ruxolitinib in combination with thalidomide in patients with myelofibrosis, released in 61st Annual Meeting and Exposition of the American Society of Hematology.
- 26 Mar 2019 Planned number of patients changed from 25 to 30.
- 08 Mar 2019 Planned End Date changed from 1 Feb 2019 to 1 Feb 2020.